|Chemical and physical data|
|Molar mass||398.37 g/mol g·mol−1|
|3D model (JSmol)|
|NY (what is this?)|
Idalopirdine (INN) (code names Lu AE58054,) is a potent and selective 5-HT6 receptor antagonist under development by Lundbeck as an augmentation therapy for the treatment of cognitive deficits associated with Alzheimer's disease and schizophrenia. As of October 2013 it is in phase III clinical trials.
A phase III trial of two different daily doses of Lu AE58054 on top of 10 mg of donepezil for mild-to-moderate Alzheimer's failed to meet its primary endpoint with either dose. Two further phase III trials failed too, the company confirmed in early 2017.
- Lundbeck expands its pipeline - initiating phase II clinical trials with a new compound for the treatment of schizophrenia
- Lundbeck initiates clinical phase II trials with Lu AE58054 as augmentation treatment in Alzheimer's disease
|AChE inhibitor medications|
|Experimental BACE inhibitors|